Clinical Trial Update: Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating romosozumab as an adjunct to physiologic estrogen replacement for functional hypothalamic amenorrhea and is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Functional Hypothalamic Amenorrhea

Drugs mentioned

• Estrogen (Estrogen)
• Romosozumab (romosozumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: FHA (Functional Hypothalamic Amenorrhea) | Phase 3 | Status: RECRUITING